[
  {
    "ts": "2025-12-03T12:26:21+00:00",
    "headline": "Tech Is Getting Left Behind in the S&P 500’s Latest Rebound",
    "summary": "Eli Lilly & Co, Cardinal Health Inc. and Biogen Inc. are among the top 10 performers in the S&P 500 since Oct. 28, the last time the index closed at a record.  In contrast, the S&P 500 Information Technology index is down 4.2% since then, with bigger losses coming from Magnificent Seven stocks like Nvidia Corp. and Microsoft Corp.  The moves suggest that investor are still skittish about the artificial intelligence trade as concerns linger about valuations and whether all the heavy spending on computing power will pay off with profits.",
    "url": "https://finance.yahoo.com/news/tech-getting-left-behind-p-122621068.html",
    "source": "Bloomberg",
    "provider": "yfinance",
    "raw": {
      "id": "6d27d5f9-23ad-31b3-8a2a-573527e1ad07",
      "content": {
        "id": "6d27d5f9-23ad-31b3-8a2a-573527e1ad07",
        "contentType": "STORY",
        "title": "Tech Is Getting Left Behind in the S&P 500’s Latest Rebound",
        "description": "",
        "summary": "Eli Lilly & Co, Cardinal Health Inc. and Biogen Inc. are among the top 10 performers in the S&P 500 since Oct. 28, the last time the index closed at a record.  In contrast, the S&P 500 Information Technology index is down 4.2% since then, with bigger losses coming from Magnificent Seven stocks like Nvidia Corp. and Microsoft Corp.  The moves suggest that investor are still skittish about the artificial intelligence trade as concerns linger about valuations and whether all the heavy spending on computing power will pay off with profits.",
        "pubDate": "2025-12-03T12:26:21Z",
        "displayTime": "2025-12-03T12:26:21Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/bloomberg_holding_pen_162/9d9c9990ef4ac9f3e53c8a0efb7119e2",
          "originalWidth": 2000,
          "originalHeight": 1333,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/SAl48l8fQmleVEUvq9UUMA--~B/aD0xMzMzO3c9MjAwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/bloomberg_holding_pen_162/9d9c9990ef4ac9f3e53c8a0efb7119e2.cf.webp",
              "width": 2000,
              "height": 1333,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/_FGrfUbJWYGnMHq.oDNFqg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/bloomberg_holding_pen_162/9d9c9990ef4ac9f3e53c8a0efb7119e2.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Bloomberg",
          "url": "https://www.bloomberg.com/company"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/tech-getting-left-behind-p-122621068.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/tech-getting-left-behind-p-122621068.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "^GSPC"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "CAH"
            },
            {
              "symbol": "BIIB"
            },
            {
              "symbol": "NVDA"
            },
            {
              "symbol": "MSFT"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-03T16:30:11+00:00",
    "headline": "Why Is Myriad (MYGN) Up 8.7% Since Last Earnings Report?",
    "summary": "Myriad (MYGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.",
    "url": "https://finance.yahoo.com/news/why-myriad-mygn-8-7-163011050.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "3618a2a0-18b4-3e13-b1c4-7fd05308c39c",
      "content": {
        "id": "3618a2a0-18b4-3e13-b1c4-7fd05308c39c",
        "contentType": "STORY",
        "title": "Why Is Myriad (MYGN) Up 8.7% Since Last Earnings Report?",
        "description": "",
        "summary": "Myriad (MYGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.",
        "pubDate": "2025-12-03T16:30:11Z",
        "displayTime": "2025-12-03T16:30:11Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/d7dcbe11345e3f8e5e71e6827fe3c4c9",
          "originalWidth": 1000,
          "originalHeight": 754,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ySW4yppQRAB0XpI0aj_Aag--~B/aD03NTQ7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/zacks.com/d7dcbe11345e3f8e5e71e6827fe3c4c9.cf.webp",
              "width": 1000,
              "height": 754,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/y7O9v2FlH8hDflZpTNqGwg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/d7dcbe11345e3f8e5e71e6827fe3c4c9.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/why-myriad-mygn-8-7-163011050.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/why-myriad-mygn-8-7-163011050.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MYGN"
            },
            {
              "symbol": "^GSPC"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-03T23:10:00+00:00",
    "headline": "Eisai Presents New Data on the Continued and Expanding Benefit of LEQEMBI® (lecanemab-irmb) Maintenance Treatment in Early Alzheimer's Disease at the Clinical Trials on Alzheimer's Disease (CTAD) Conference 2025",
    "summary": "Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, \"Eisai\") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, \"Biogen\") announced today that the latest findings on time savings with continued treatment with humanized anti-soluble aggregated amyloid-beta (Aβ) monoclonal antibody lecanemab (generic name, U.S. brand name LEQEMBI®) were presented at the 18th Clinical Trials on Alzheimer's Disease (CTAD) Conference. Additionally, a s",
    "url": "https://finance.yahoo.com/news/eisai-presents-data-continued-expanding-231000717.html",
    "source": "PR Newswire",
    "provider": "yfinance",
    "raw": {
      "id": "a5d248ab-a6c3-33c7-aece-280e38111690",
      "content": {
        "id": "a5d248ab-a6c3-33c7-aece-280e38111690",
        "contentType": "STORY",
        "title": "Eisai Presents New Data on the Continued and Expanding Benefit of LEQEMBI® (lecanemab-irmb) Maintenance Treatment in Early Alzheimer's Disease at the Clinical Trials on Alzheimer's Disease (CTAD) Conference 2025",
        "description": "",
        "summary": "Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, \"Eisai\") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, \"Biogen\") announced today that the latest findings on time savings with continued treatment with humanized anti-soluble aggregated amyloid-beta (Aβ) monoclonal antibody lecanemab (generic name, U.S. brand name LEQEMBI®) were presented at the 18th Clinical Trials on Alzheimer's Disease (CTAD) Conference. Additionally, a s",
        "pubDate": "2025-12-03T23:10:00Z",
        "displayTime": "2025-12-03T23:10:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/prnewswire.com/8fbe328e0f2d5337d2839c8345101b15",
          "originalWidth": 400,
          "originalHeight": 112,
          "caption": "Eisai logo and Biogen logo (PRNewsfoto/Eisai Co., Ltd.)",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/bJrlns2nzwpK84mfnZzsTg--~B/aD0xMTI7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/8fbe328e0f2d5337d2839c8345101b15.cf.webp",
              "width": 400,
              "height": 112,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/lpiHqXXYlwJmL4_lRc2Yvw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/8fbe328e0f2d5337d2839c8345101b15.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "PR Newswire",
          "url": "https://www.prnewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/eisai-presents-data-continued-expanding-231000717.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/eisai-presents-data-continued-expanding-231000717.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ESAIY"
            },
            {
              "symbol": "BIIB"
            },
            {
              "symbol": "ESALF"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]